NCT01433731 2016-03-24Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)TetraLogic PharmaceuticalsPhase 1 Completed18 enrolled 7 charts